Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FOSTER CITY, Calif. --(BUSINESS WIRE)--May 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500 shares of common stock to 9
- NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is September 29, 2021 - Received additional $65.0 million in funding from Oberland Capital based on NDA acceptance - Commercial team hired in anticipation of U.S.
FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced that the company will report financial results for the quarter ended March 31, 2021 on Thursday, May 6, 2021 . That same day, Mirum will host a conference call and audio webcast at
- CANbridge to lead development and commercialization in China ; expands rare disease pipeline - Mirum is entitled to receive up to an aggregate of $120.0 million in upfront and milestone payments, and significant double-digit tiered royalties FOSTER CITY, Calif. & BEIJING --(BUSINESS WIRE)--Apr.